MoneyWorks4Me

Glenmark Pharma gets USFDA’s nod for Fluticasone Propionate Nasal Spray

20 Aug 2026 Evaluate

Glenmark Pharmaceuticals has received USFDA’s approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. The company’s Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC (NDA 020121) and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. 

According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market achieved annual sales of around $295.2 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries.

Glenmark Pharma. Share Price

2306.00 -19.00 (-0.82%)
21-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1900.90
Dr. Reddys Labs. 1175.00
Cipla 1426.20
Lupin 2193.00
Zydus Lifesciences 1120.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: